QPS Holdings Implements Oracle Argus Platform to Enhance Clinical Trial Safety Management
核心洞察
QPS Holdings (搜索), a global contract research organization with over 1,200 employees, has implemented Oracle Argus (搜索) as its new clinical trial pharmacovigilance system to advance safety case management across drug development activities.
The platform integration enables improved capture, management, and reporting of adverse events in compliance with global regulatory requirements while optimizing pharmacovigilance workflows.
The adoption aims to support pharmaceutical sponsors' growing clinical trial portfolios by balancing rapid development timelines with enhanced patient safety and data integrity standards.
US-based contract research organization QPS Holdings (搜索) has implemented Oracle Argus (搜索) as its new clinical trial pharmacovigilance system, marking a significant advancement in safety case management capabilities for drug development activities. The adoption aims to improve regulatory compliance, patient safety, and operational standards across QPS clients globally.
Enhanced Safety Monitoring Capabilities
The integration of Oracle Argus (搜索) enables QPS to better capture, manage, and report adverse events in line with global regulatory requirements. Key benefits include improved support for client safety monitoring, increased traceability throughout clinical development stages, optimized pharmacovigilance workflows, and greater efficiency in global regulatory submissions.
As demand for new therapies rises worldwide, contract research organizations such as QPS are emphasizing their role in balancing rapid development timelines with patient safety. By leveraging the Oracle Argus (搜索) platform as its clinical trial pharmacovigilance system, QPS aims to meet the requirements of pharmaceutical sponsors seeking advanced research services.
Global CRO Operations
QPS operates as a global contract research organization with over 1,200 employees across Asia, Europe, India, and the US. The company offers bioanalysis, discovery, preclinical and clinical development services and holds experience in areas including drug metabolism and pharmacokinetics (DMPK), pharmacology, translational medicine, toxicology, central safety labs, peripheral blood mononuclear cell (PBMC) processing, multi-site research operations, and Phase I/II clinical units.
Leadership Perspectives
"Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials," said QPS executive vice-president Derek Grimes. "Oracle Argus (搜索) provides us with a robust, scalable solution to support the growing needs of our customers' clinical trial portfolios and the evolving expectations of regulatory authorities worldwide."
Oracle (搜索) Health and Life Sciences executive vice-president and general manager Seema Verma emphasized the platform's capabilities: "Oracle Argus (搜索) provides QPS Holdings (搜索) with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations while streamlining end-to-end safety operations and insights at scale. With our industry-leading solutions, QPS Holdings can further transform and elevate its safety case management for customers worldwide."
Strategic Partnerships
In January 2025, Ryght AI (搜索) announced a strategic collaboration with QPS Holdings (搜索) to optimize clinical trial processes on a global scale, further expanding the company's technological capabilities in clinical research operations.